Axogen, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Axogen, Inc. (AXGN) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $854.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-07-29
- Axogen, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $434.00K, a 347.42% increase year-over-year.
- Axogen, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $420.00K, a 382.76% increase year-over-year.
- Axogen, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $1.24M, a 478.97% increase year-over-year.
- Axogen, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $110.00K, a 55.47% decline year-over-year.
- Axogen, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.53M, a 38.98% increase from fiscal 2024.
- Axogen, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.10M, a 3.86% increase from fiscal 2023.
- Axogen, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.06M, a 39.69% decline from fiscal 2022.
- Axogen, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.76M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $434.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $854.00K 10-Q · filed 2026-07-29 | $2.09M derived: sum of 3 quarters · filed 2026-07-29 | $2.20M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $420.00K 10-Q · filed 2026-04-28 | $1.66M derived: sum of 2 quarters · filed 2026-04-28 | $1.77M derived: sum of 3 quarters · filed 2026-04-28 | $1.87M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.35M derived: sum of 2 quarters · filed 2026-02-24 | $1.45M derived: sum of 3 quarters · filed 2026-07-29 | $1.53M 10-K · filed 2026-02-24 |
| 2025-09-30 | $110.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $207.00K derived: sum of 2 quarters · filed 2026-07-29 | $294.00K 10-Q · filed 2025-10-29 | $508.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $97.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $184.00K 10-Q · filed 2026-07-29 | $398.00K derived: sum of 3 quarters · filed 2026-07-29 | $645.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $87.00K 10-Q · filed 2026-04-28 | $301.00K derived: sum of 2 quarters · filed 2026-04-28 | $548.00K derived: sum of 3 quarters · filed 2026-04-28 | $875.00K derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $214.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $461.00K derived: sum of 2 quarters · filed 2026-02-24 | $788.00K derived: sum of 3 quarters · filed 2026-02-24 | $1.10M 10-K · filed 2026-02-24 |
| 2024-09-30 | $247.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $574.00K derived: sum of 2 quarters · filed 2025-10-29 | $889.00K 10-Q · filed 2025-10-29 | $1.13M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $327.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $642.00K 10-Q · filed 2025-08-05 | $878.00K derived: sum of 3 quarters · filed 2026-02-24 | $1.06M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $315.00K 10-Q · filed 2025-05-08 | $551.00K derived: sum of 2 quarters · filed 2026-02-24 | $735.00K derived: sum of 3 quarters · filed 2026-02-24 | $913.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $236.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $420.00K derived: sum of 2 quarters · filed 2026-02-24 | $598.00K derived: sum of 3 quarters · filed 2026-02-24 | $1.06M 10-K · filed 2026-02-24 |
| 2023-09-30 | $184.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $362.00K derived: sum of 2 quarters · filed 2024-11-07 | $826.00K 10-Q · filed 2024-11-07 | $1.28M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $178.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $642.00K 10-Q · filed 2024-08-08 | $1.10M derived: sum of 3 quarters · filed 2025-02-26 | $1.54M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $464.00K 10-Q · filed 2024-05-02 | $922.00K derived: sum of 2 quarters · filed 2025-02-26 | $1.37M derived: sum of 3 quarters · filed 2025-02-26 | $1.80M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $458.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $902.00K derived: sum of 2 quarters · filed 2025-02-26 | $1.33M derived: sum of 3 quarters · filed 2025-02-26 | $1.76M 10-K · filed 2025-02-26 |
| 2022-09-30 | $444.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $876.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.30M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $432.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $859.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $427.00K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| LivaNova PLC (LIVN) | $4.158B | 24.01 | |
| Integer Holdings Corp (ITGR) | United States | $4.289B | 25.17 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |